Ultrasonography survey and thyroid cancer in the Fukushima Prefecture
Thyroid cancer is one of the major health concerns after the accident in the Fukushima Dai-ichi nuclear power station (NPS). Currently, ultrasonography surveys are being performed for persons residing in the Fukushima Prefecture at the time of the accident with an age of up to 18 years. Here, the expected thyroid cancer prevalence in the Fukushima Prefecture is assessed based on an ultrasonography survey of Ukrainians, who were exposed at an age of up to 18 years to 131I released during the Chernobyl NPS accident, and on differences in equipment and study protocol in the two surveys. Radiation risk of thyroid cancer incidence among survivors of the atomic bombings of Hiroshima and Nagasaki and preliminary estimates of thyroid dose due to the Fukushima accident were used for the prediction of baseline and radiation-related thyroid cancer risks. We estimate a prevalence of thyroid cancer of 0.027 % (95 % CI 0.010 %; 0.050 %) for the first screening campaign in the Fukushima Prefecture. Compared with the incidence rate in Japan in 2007, the ultrasonography survey is predicted to increase baseline thyroid cancer incidence by a factor of 7.4 (95 % CI 0.95; 17.3). Under the condition of continued screening, thyroid cancer during the first fifty years after the accident is predicted to be detected for about 2 % of the screened population. The prediction of radiation-related thyroid cancer in the most exposed fraction (a few ten thousand persons) of the screened population of the Fukushima Prefecture has a large uncertainty with the best estimates of the average risk of 0.1–0.3 %, depending on average dose.
KeywordsFukushima Radiation Thyroid cancer Ultrasonography
Large amounts of radionuclides were released from the Fukushima Dai-ichi nuclear power station (NPS) in the aftermath of the 2011 Great East Japan earthquake, tsunami and reactor accident. Thanks to prompt actions of Japanese authorities, radiation exposures of the population were generally low. However, average thyroid doses of young children in some settlements were reported to be of the order of or even exceeding 100 mSv (WHO 2013). These dose estimates are based on measurements on environmental and food samples (WHO 2012). In contrast, measurements of incorporated 131I indicate that thyroid doses in the population were lower than the WHO estimate (Kamada et al. 2012; Tokonami et al. 2012; Kim et al. 2013; Matsuda et al. 2013).
There is concern about thyroid cancer induced by the accident at the Fukushima Dai-ichi NPS. The concern is caused by the massive increase in thyroid cancer among those who were highly exposed during childhood due to the Chernobyl accident (Kazakov et al. 1992; UNSCEAR 2011). In order to monitor thyroid cancer, periodic thyroid ultrasonography surveys have been introduced for all inhabitants of the Fukushima Prefecture who were 18 years old or younger at the time of the accident (Fukushima Medical University 2013a).
Thyroid cancer is a rare disease, although thyroid cancer incidence has increased worldwide during the previous decades. This increase might be related to improved diagnostics. No evidence for an influence of stable iodine supply could be demonstrated in a Danish study comparing thyroid cancer incidence before and after iodine supplementation (Bloomberg et al. 2012). Ultrasonography has a large potential of detecting so-called occult carcinoma that do not become clinically relevant during lifetime (Welch and Black 2010; Moynihan et al. 2012). The existence of such carcinoma has been demonstrated by autopsies with prevalence values ranging from 1.5 % in Greece (Delides et al. 1987) to 36 % in Finland (Harach et al. 1985). Different definitions of prevalence are given in the literature. In the present paper, ‘proportion of a population that has a disease at a specific point in time’ is used as a definition (Rothmann and Greenland 1998). In contrast, incidence rate is defined as number of new cases reported per year and per number of persons in the population under continuing practices of detection and reporting. Thus, the first campaign of the new programme of ultrasonography surveys yields the prevalence of thyroid cancer, and subsequent campaigns the incidence rate among people who already participated in the first campaign.
Autopsies of 2,372 of otherwise cancer-free survivors of the atomic bombings of Hiroshima and Nagasaki revealed 106 papillary thyroid microcarcinoma, mostly of the sclerosing variant (Hayashi et al. 2010). This corresponds to a prevalence of 4.5 %. The autopsy results apply mainly to adults. No conclusive data on occult thyroid cancer in children are available. The number of occult carcinomas detected by ultrasonography depends on the equipment and study protocol used. Several other factors like the age–gender structure of the cohort and the country-specific or even group-specific thyroid cancer frequency influence prevalence (first screening) and incidence rate (subsequent screenings) in ultrasonography surveys.
As of 31 July 2013, ultrasonography has been performed on 11 March 2011 for 41,296 children, adolescents and young adults living in thirteen municipalities of the Fukushima Prefecture that were targeted for screening before April 2012 (Fukushima Medical University 2013a). A secondary examination was required for 214 persons with thyroid nodules larger than 5 mm or cysts larger than 20 mm. These examinations were completed for 165 persons allowing a first estimation of thyroid cancer prevalence in the young population. Cytology of fine needle aspiration (FNA) biopsies revealed 14 cases of suspected malignancy. Surgery has been performed for 10 of them; 9 were identified as papillary carcinoma, one as a benign tumour. The 13 cases of confirmed (9) or still suspected (4) thyroid cancer correspond to a prevalence of 13/41,296 = 0.031 %. The prevalence is expected to increase because of possible thyroid cancer cases among the 49 persons for whom secondary examination was required but not completed by 31 July 2013.
In a second group of municipalities that were targeted for screening between April 2012 and March 2013, 135,586 people were screened and 30 cases of suspected thyroid cancer were detected by cytology of FNA biopsies. Only 55 % of the required secondary examinations were already finished by 31 July 2013; thus, the prevalence in these municipalities is expected to increase beyond the present value of 0.022 %.
Ultrasonography has been performed for the UkrAm cohort consisting of Ukrainians who were 18 years old or younger on 26 April 1986, the date of the Chernobyl accident (Tronko et al. 2006). Concerning sex–age distribution of the cohort at the time of the accident and baseline incidence rate (National Cancer Register of Ukraine 2013), the cohort is comparable with the study group in the Fukushima Prefecture. However, the first screening was performed from 1998 to 2000, i.e. 12–14 years after exposure. The study protocol selected nodules sized from 5 to 10 mm for secondary examination only, if further criteria (such as hypoechoic nodule, or nodules with microcalcifications, having irregular contour or extension through the thyroid capsule, or suspicious lymph nodes) were fulfilled (O’Kane et al. 2010). Thus, this protocol leads under otherwise same conditions to a smaller prevalence than the study protocol in the Fukushima Prefecture. Nevertheless, prevalence of confirmed thyroid cancer cases in the UkrAm cohort, which were assessed to be not related to the exposure from the Chernobyl accident, was higher than what is expected for the Fukushima Prefecture, because cohort members at the time of the first screening were older, in average by about 12 years.
Repeated ultrasonography was also performed for the UkrAm cohort (Brenner et al. 2011). Comparison with the baseline thyroid cancer incidence rate in Ukraine allows an assessment of the impact of the screening on reported incidence rates. The effect of an increased surveillance of the thyroid was also analysed for Belarusian and Ukrainian population groups (Jacob et al. 2006a; Likhtarov et al. 2006). Based on these three studies, in the present paper, the baseline (not related to the radiation exposure due to the accident at the Fukushima Dai-ichi NPS) thyroid cancer incidence rate in the Fukushima Prefecture under the conditions of ongoing surveys is estimated.
Long-term thyroid cancer risk due to exposure to external ionizing radiation has been analysed in a number of studies (Ron et al. 1995; Furukawa et al. 2013; Veiga et al. 2012). However, higher thyroid doses among inhabitants of the Fukushima Prefecture were mainly caused by incorporation of radioiodine (WHO 2012). For young age at exposure to radioiodine and the first 20 years after the Chernobyl accident, an increased risk has been demonstrated (Tronko et al. 2006; Brenner et al. 2011; Cardis et al. 2005; Kopecky et al. 2006; Jacob et al. 2006b). However, the risk information is less complete than for external exposures. In the present study, radiation risks from data of the atomic bomb survivors are derived and the consistency with results obtained in studies on people exposed to 131I from the Chernobyl nuclear power plant is investigated. The LSS risk function is used to predict excess rates in the Fukushima Prefecture by applying a screening factor that is based on experiences in the UkrAm cohort and differences in the study protocol of the ultrasonography surveys.
Materials and methods
Study groups, screening intervals and thyroid dose
The Fukushima Health Management Survey includes ultrasonography of the thyroid of all residents of the Fukushima Prefecture aged up to 18 years on 11 March 2011 (Fukushima Medical University 2013a). Based on post-Chernobyl studies, we calculated thyroid cancer prevalence for two campaigns of the first screening, October 2011 to March 2012, and April 2012 to March 2013 (see Supporting Information for sex–age distributions). Prevalence is also calculated for the sex–age distribution in the ultrasonography survey of children and adolescents in the three non-contaminated prefectures of Aomori, Yamanashi und Nagasaki (Taniguchi et al. 2013).
According to WHO (2013), in one scenario, an average thyroid dose of 50 mSv for the most exposed fraction (a few ten thousand persons) of the surveyed population in the Fukushima Prefecture is assumed here. Since measurements of the iodine content indicate lower doses (Kamada et al. 2012; Kim et al. 2013; Matsuda et al. 2013; Tokonami et al. 2012), however, in a second scenario, an average thyroid dose of 20 mSv was also assumed. Note that individual thyroid doses could have been considerably larger or smaller. For a linear dose response, however, excess incidence rate is determined by the average dose and not by other parameters of the dose distribution.
Thyroid cancer prevalence detected by ultrasonography
The UkrAm cohort consists of 13,127 Ukrainians who were up to 18 years old on 26 April 1986, the date of the Chernobyl accident (Tronko et al. 2006). During the time of the first screening in the UkrAm cohort, the age-standardized thyroid cancer incidence rate in Ukraine was 1.2 and 4.9 cases per 105 person-years for males and females, respectively (National Cancer Registry of Ukraine 2013). These rates are comparable with those in Japan in 2007 of 2.2 and 7.9 cases per 105 person-years (National Cancer Center 2012). The first round of ultrasonography in the UkrAm cohort was performed 12–14 years after the accident, and 45 pathologically confirmed thyroid cancer cases were detected. Tronko et al. estimated that 11.2 (95 % CI 3.2; 22.5) of these cases would have been detected in the absence of the exposure due to the Chernobyl accident. This corresponds to a prevalence, PUA, of about 0.09 (95 % CI 0.02; 0.17) %.
No direct information is available to determine fsp for tumours. As a surrogate, the corresponding ratio for nodules is used instead. This choice is supported by the thyroid screening study in Hong Kong (Yuen et al. 2011), in which the ratio for nodules larger than 5 mm and larger than 10 mm is 2.4 (398/169). For tumours, the ratio is 2.2 (11/5), nearly equal to that for nodules. The screenings from October 2011 to March 2013 in the Fukushima Prefecture detected 1,125 nodules larger than 5 mm and 354 nodules larger than 10 mm (Fukushima Medical University 2013b). Correspondingly, the upper boundary of fsp is estimated to be 1,125/354 = 3.2. The lower boundary is assumed to correspond to no additional cases according to differences in the study protocol, 1.0. The factor fsp is assumed to have a symmetrical triangular distribution between these two boundaries with a maximum at 2.1.
Impact of ultrasonography and thyroid surveillance on thyroid cancer incidence rate
Thus, the distribution of the screening factor in the Fukushima Prefecture, Fscr, is a product of the screening factor in the UkrAm cohort, fUA, and the factor taking into account differences in the study protocol, fsp.
Thyroid cancer risk in LSS
These two time periods were chosen to differentiate the early period with many autopsies from the later period with fewer autopsies (Preston et al. 2007). More details on the risk models and their parameters are given in the Electronic Supplementary Material.
Excess absolute rate in the Fukushima Prefecture
Lifetime attributable risk refers to an integration period from exposure over the whole lifetime.
Risks for the study group are calculated by averaging over the sex–age distribution at the time of exposure.
Thyroid cancer prevalence
Expected prevalence of confirmed thyroid cancer among screened population groups targeted for the Fukushima Health Management Survey before April 2012, for the period from April 2012 to March 2013, and in the non-contaminated prefectures of Aomori, Yamanashi and Nagasaki (Taniguchi et al. 2013). Hypothetical thyroid cancer incidence rate without screening according to cancer registry data for Japan in 2007 is added to demonstrate the dependence on age
Study group in prefecture(s)
Period of screening
Hypothetical incidence rate without screening (PY−1)
Estimated prevalence (%)a
Oct 2011–Mar 2012
0.267 × 10−5
0.027 (0.010; 0.050)
Apr 2012–Mar 2013
0.332 × 10−5
0.034 (0.013; 0.061)
Aomori, Yamanashi and Nagasaki
Nov 2012–Jan 2013
0.317 × 10−5
0.032 (0.012; 0.057)
Prevalence for the municipalities of the Fukushima Prefecture targeted for later periods is predicted to be somewhat higher, because the screening has been performed later; thus, mean age in the cohort at the time of screening and, correspondingly, average hypothetical incidence rate without screening are higher (see Table 1).
Screening factors due to ultrasonography surveys
Thyroid cancer incidence rate in the Fukushima Prefecture under the condition of continued ultrasonography surveys is estimated to be increased compared with the incidence rate in 2007 by a factor of 7.4, with a 95 % confidence range from 0.96 to 17.3. Because of differences in the study protocol, the screening factor in the Fukushima Prefecture is larger and has a wider confidence interval than that in the UkrAm cohort.
Thyroid cancer incidence risk in the LSS
The impact of screening and autopsies on thyroid cancer incidence among AHS participants was relatively small. For the period before 1970 with a relatively high rate of autopsies, we find a screening factor of 1.72 (95 % CI 1.17; 2.55), and for the period afterwards of 1.23 (95 % CI 0.96; 1.59).
Attributable risk rate
For exposure at older age, the increase is less steep. The attributable risk rate reaches a flat maximum at the attained age of about 60 years and decreases subsequently due to the decrease in the survival function.
In general, best estimates of the attributable risk rate for females are larger than those for males. The ratio is maximal for an attained age of about 40 years with a value of 5.5 for age at exposure of 1 year. The difference is, however, not significant due to the large uncertainty of the estimates. Main sources of uncertainty are the risk function derived from the LSS, the screening factor, and extrapolation of the risk function to low dose rates (in the order of decreasing importance).
With the exception of young attained age, the multiplicative transfer, Eq. (4), gives results very similar to the mixed transfer. For boys below attained age of 15 years and girls below age of 10, the multiplicative transfer results in no excess cases, whereas the mixed transfer gives non-zero results.
Baseline and radiation-attributable thyroid cancer risk (mean value and 95 % confidence interval) after an exposure with a hypothetical thyroid dose of 100 mSv for different time periods after exposure
Age at exposure (years)
Thyroid cancer risk (%) for different periods after exposure with a thyroid dose of 100 mSv
0.0 (0.0; 0.0)
0.026 (0.003; 0.065)
0.52 (0.06; 1.2)
0.014 (<10−4; 0.090)
0.054 (0.002; 0.26)
0.30 (0.015; 1.2)
0.0029 (2 × 10−4; 0.0088)
0.089 (0.012; 0.22)
2.3 (0.31; 5.5)
0.013 (3 × 10−4; 0.069)
0.12 (0.007; 0.51)
1.4 (0.11; 4.6)
0.021 (0.003; 0.053)
0.11 (0.015; 0.27)
0.91 (0.12; 2.2)
0.019 (6 × 10−4; 0.088)
0.059 (0.003; 0.24)
0.24 (0.013; 0.87)
0.071 (0.008; 0.18)
0.33 (0.04; 0.80)
3.6 (0.44; 8.7)
0.042 (0.002; 0.19)
0.16 (0.008; 0.59)
0.94 (0.058; 3.1)
0.080 (0.010; 0.20)
0.20 (0.026; 0.50)
1.2 (0.16; 3.0)
0.018 (7 × 10−4; 0.077)
0.047 (0.002; 0.19)
0.18 (0.009; 0.64)
0.22 (0.026; 0.52)
0.79 (0.091; 1.8)
4.7 (0.54; 11)
0.044 (0.002; 0.17)
0.15 (0.007; 0.55)
0.63 (0.03; 2.0)
For the same thyroid dose, the attributable risk accumulating over several decades after exposure decreases with increasing age at exposure. However, the effect is relatively modest (about a factor of two for ages at exposure of 1 and 18 years).
Predicted thyroid cancer risk (mean and 95 % confidence interval) in the Fukushima Prefecture: baseline and attributable to radiation exposure for thyroid doses of 50 and 20 mSv assumed for the most exposed population groups
Average thyroid dose (mSv)
Thyroid cancer risk (%) for different periods after exposure
0.055 (0.006; 0.14)
0.23 (0.027; 0.58)
2.2 (0.27; 5.3)
0.0057 (0.0002; 0.025)
0.021 (0.0007; 0.081)
0.13 (0.005; 0.40)
0.014 (0.0004; 0.063)
0.053 (0.002; 0.20)
0.32 (0.011; 1.0)
Thyroid cancer prevalence
The first ultrasonography survey in the Fukushima Prefecture is intended to be finished at 31 Mar 2014, about 3 years after the accident at Fukushima Dai-ichi NPS. After the Chernobyl accident, an excess of thyroid cancer cases was not observed before 3 years after exposure (Heidenreich et al. 1999). Thus, the prevalent cases in the Fukushima Prefecture are not assumed to be related to radiation exposure.
four persons having suspected malignancy according to cytology of FNA biopsies had not been operated before 31 July 2013;
only 165 out of 214 individuals, for whom secondary examination was required, have finished such an examination.
Thus, the results obtained so far by the survey are in agreement with our calculations that resulted in a prevalence of 0.027 (0.010; 0.050) % (Table 1).
Screening factors in post-Chernobyl studies
In a population-based study of Likhtarov et al. (2006), population groups with ultrasonography frequency of more than 1.8 % and less than 0.7 % have been compared. They estimated thyroid cancer incidence rate in the former group to be larger by a factor of 3.3 than in the latter. For Ukrainian oblasts with high thyroid exposures due to the Chernobyl accident and for most oblasts in Belarus, baseline thyroid cancer incidence in 1999 compared with 1988 was assessed to be higher by a factor of about three (Jacob et al. 2006a). This effect was attributed to an increased surveillance of the thyroid. The present result of the screening factor in the UkrAm cohort of 3.6 (95 % CI 0.5; 7.9) is consistent with the assessment of the two population-based studies mentioned above.
Thyroid cancer risk in atomic bomb survivors versus post-Chernobyl studies
The excess absolute rate depends on the screening conditions. It is relatively small for the LSS members not participating in the AHS (Fig. 4, lower panel, blue dashed line). Applying the full screening factor, Fscr, leads to an EAR estimate (Fig. 4, lower panel, blue solid line) that tends to be higher than what was observed in the UkrAm cohort. This is plausible, because the study protocol in the Fukushima Prefecture is expected to lead to a higher screening effect than in the UkrAm cohort. Indeed, if the screening factor for the UkrAm cohort fUA is applied to EARLSS, then good agreement with the excess absolute rate per unit dose in the UkrAm cohort is obtained (curve not depicted in Fig. 4).
Overall, these comparisons do not give any evidence against the application of the LSS risk function and the screening factor Fscr to populations screened in the Fukushima Prefecture.
Attributable risk rate
In our approach with a mixed transfer of excess risk estimates from the LSS to the population in the Fukushima Prefecture, the attributable risk rate increases steeply after a minimal latency period of 3 years. In contrast, according to the multiplicative transfer, excess cases do not appear before attained age of 15 for males and age attained 10 for females. The latter approach is not in accordance with experiences after the Chernobyl accident, however, where many excess cases were observed before attained age of 10 years (UNSCEAR 2011).
According to the results shown in Table 2 for an age of exposure of 1 year, about 15 % of the attributable risk accumulated over 20 years is contributed by the first 10 years after exposure. For an age of exposure of 10 years, we obtain a contribution of 30 %. These predictions compare well to thyroid cancer incidence after the Chernobyl accident. In Belarus, for example, where most of the observed thyroid cancer incidence was attributed to radiation exposure (Jacob et al. 2006a), 29 % of thyroid cancer cases during the first 20 years after exposure occurred during the first 10 years for the age-at-exposure group of 0–4 years, and 35 % for the age-at-exposure group of 5–9 years (UNSCEAR 2011).
Another check of consistency with post-Chernobyl experiences relates to age-at-exposure dependence. According to our prediction, the attributable risk accumulated over the first 20 years after exposure is about the same for ages at exposure of 1 and 10 years, if the thyroid dose is the same. In Belarus, the number of cases was higher for the age-at-exposure group of 0–4 years than for the age-at-exposure group of 5–9 years by a factor of 1.7 (UNSCEAR 2011). Thyroid doses differed by a similar factor (Jacob et al. 2006a).
Finally, we predict the excess rate during the first 20 years after exposure among females to be higher than among males by a factor of 2–3. Again, in Belarus, the risk was higher by a factor of 2.6 (crude rate among females of 6.7 versus 2.6 per 104 person-years for males, according to UNSCEAR (2011)).
Whereas our predictions for the first 20 years after exposure are supported by some studies of thyroid cancer after the Chernobyl accident, our longer-time predictions are more uncertain and may overestimate the risk. This is so because we have neglected a so-called harvesting effect that might appear after 20 years after exposure: Early detection may lead to lower numbers of detected cases at later campaigns of a survey. However, we are not aware of studies that give evidence of a harvesting effect of ultrasonography for thyroid cancer incidence.
For a period of 50 years after exposure at ages at exposure of up to 18 years, we predict that an average thyroid dose of 20 mSv would result in a relative contribution of about 6 % to the total thyroid cancer risk. This is in accordance with the results of WHO (2013), because of the close similarity of the approaches applied concerning relative risks. Concerning the total thyroid cancer risk, however, our results are higher by a factor of about 7, because WHO did not consider in its calculations the impact of the ultrasonography survey.
Based on the results presented here, it is expected that the ultrasonography survey of residents of Fukushima Prefecture will increase thyroid cancer incidence compared with thyroid cancer incidence in 2007 in Japan drastically. The estimated increase has a large uncertainty with a best estimate of a factor of about 7. For an average thyroid dose of 20 mSv of the most exposed in the surveyed population, it is estimated that in the early period, about 10 % and in later periods about 5 % of the reported incidence will be attributable to radiation exposure. Thus, the fraction of thyroid cancer cases attributable to radiation exposure will be small, although there are regional differences due to varying doses. The present assessment includes large uncertainties caused by uncertainties in the thyroid cancer risk function for the LSS, the impact of the ultrasonography survey, and the transfer of the risk function to low-dose exposures to 131I. Independent of these uncertainties, however, the order of magnitude of the predicted thyroid cancer prevalence and incidence rate may help to be prepared for a relatively large number of thyroid cancer cases that are to be expected. It is emphasized that most of the cases would not have become clinically relevant without the ultrasonography survey.
The study has been partially supported by EC-funded project EpiRadBio under contract 269553 and by German Federal Office for Radiation Protection (BfS) under contracts 3607S04570 and 3612S70030. This report makes use of data obtained from the Radiation Effects Research Foundation (RERF) in Hiroshima and Nagasaki, Japan. RERF is a private, non-profit foundation funded by the Japanese Ministry of Health, Labour and Welfare (MHLW) and the U.S. Department of Energy (DOE), the latter through the National Academy of Sciences. The data include information obtained from the Hiroshima City, Hiroshima Prefecture, Nagasaki City, and Nagasaki Prefecture Tumor Registries and the Hiroshima and Nagasaki Tissue Registries. The conclusions in this report are those of the authors and do not necessarily reflect the scientific judgment of RERF or its funding agencies. Authors thank Dr. Kyoji Furukawa from RERF (Hiroshima, Japan) for many useful discussions and for sharing the most recent information.
- Brenner AV, Tronko MD, Hatch M, Bogdanova TI, Oliynik VA, Lubin JH, Zablotska LB, Tereschenko VP, McConnell RJ, Zamotaeva GA, O’Kane P, Bouville AC, Chaykovskaya LV, Greenebaum E, Paster IP, Shpak VM, Ron E (2011) I-131 dose-response for incident thyroid cancers in Ukraine related to the Chornobyl accident. Environ Health Persp 119(7):933–939CrossRefGoogle Scholar
- Cardis E, Kesminiene A, Ivanov V, Malakhova I, Shibata Y, Khrouch V, Drozdovitch V, Maceika E, Zvonova I, Vlassov O, Bouville A, Goulko G, Hoshi M, Abrosimov A, Anoshko J, Astakhova L, Chekin S, Demidchik E, Galanti R, Ito M, Korobova E, Lushnikov E, Maksioutov M, Masyakin V, Nerovnia A, Parshin V, Parshkov E, Piliptsevich N, Pinchera A, Polyakov S, Shabeka N, Suonio E, Tenet V, Tsyb A, Yamashita S, Williams D (2005) Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst 97:724–732CrossRefGoogle Scholar
- Delides GS, Elemenoglou J, Lekkas J, Kittas C, Evthimiou C (1987) Occult thyroid carcinoma in a greek population. Neoplasma 34:119–125Google Scholar
- Fedorenko ZP, Goulak LO, Gorokh YL, Soumkina OV, Ryzhov AYu, Koutsenko LB, Romanov DV (2002) Cancer in Ukraine, 2000–2001. Incidence, mortality, activities of oncological service. Bulletin of National Cancer Registry of Ukraine. National Cancer Registry of Ukraine, KyivGoogle Scholar
- Fukushima Medical University (2013a) Fukushima Health Management Survey. Results of thyroid ultrasound examination. http://www.fmu.ac.jp/radiationhealth/results/media/12-2_ThyroidUE.pdf. Accessed 25 November 2013
- Fukushima Medical University (2013b) Fukushima Health Management Survey. Results of thyroid ultrasound examination. http://www.fmu.ac.jp/radiationhealth/results/media/11-2_ThyroidUE.pdf. Accessed 27 November 2013
- Jacob P, Bogdanova TI, Buglova E, Chepurniy M, Demidchik Y, Gavrilin Y, Kenigsberg J, Kruk J, Schotola C, Shinkarev S, Tronko MD, Vavilov S (2006a) Thyroid cancer among Ukrainians and Belarusian who were children or adolescents at the time of the Chernobyl accident. J Radiol Prot 26:51–67CrossRefGoogle Scholar
- Jacob P, Bogdanova TI, Buglova E, Chepurniy M, Demidchik Y, Gavrilin Y, Kenigsberg J, Meckbach R, Schotola C, Shinkarev S, Tronko MD, Ulanovsky A, Vavilov S, Walsh L (2006b) Thyroid cancer risk in areas of Ukraine and Belarus affected by the Chernobyl accident. Radiat Res 165:1–8CrossRefGoogle Scholar
- Kim E, Kurihara O, Suzuki T, Matsumoto M, Fukutso K, Yamada Y, Sugiura N, Akashi M (2013) Screening survey on thyroid exposure for children after the fukushima daiichi nuclear power station accident. In: Kurihara O et al. (eds) Proceedings of the 1st NIRS symposium on reconstruction of early internal dose in the TEPCO Fukushima Daiichi power station accident. NIRS-M-252. NIRS, Chiba, pp 59–66Google Scholar
- Kopecky KJ, Stepanenko V, Rivkind N, Voillequé P, Onstad L, Shakhtarin V, Parshkov E, Kulikov S, Lushnikov E, Abrosimov A, Troshin V, Romanova G, Doroschenko V, Proshin A, Tsyb A, Davis S (2006) Childhood thyroid cancer, radiation dose from Chernobyl, and dose uncertainties in Bryansk Oblast, Russia: a population-based case-control study. Radiat Res 166:367–374CrossRefGoogle Scholar
- National Cancer Center (2012) Cancer incidence from cancer registries in Japan (1975–2007). Center for Cancer Control and Information Services, National Cancer Center, Japan. URL: http://ganjoho.jp/pro/statistics/en/table_download.html. Accessed 19 December 2012
- National Cancer Registry of Ukraine (2013) Cancer in Ukraine. URL: www.i.com.ua/~ucr. Accessed 20 Apr 2013
- National Research Council (2006) Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2. National Academy Press, WashingtonGoogle Scholar
- O’Kane P, Shelkovoy E, McConnell RJ, Shpak V, Parker L, Brenner A, Zablotska L, Tronko M, Hatch M (2010) Frequency of undetected thyroid nodules in a large I-131-exposed population repeatedly screened by ultrasonography: results from the Ukrainian–American cohort study of thyroid cancer and other thyroid diseases following the Chornobyl accident. Thyroid 20:959–964CrossRefGoogle Scholar
- Rothmann KJ, Greenland S (1998) Modern epidemiology. Lippincott-Raven, PhiladelphiaGoogle Scholar
- Taniguchi N, Hayashida N, Shimura H, Okubo N, Asari Y, Nigawara T, Midorikawa S, Kotani K, Nakaji S, Imaizumi M, Ohtsuru A, Akamizu T, Kitaoka M, Suzuki S, Yamashita S, Takamura N, The Investigation Committee for the Proportion of Thyroid Ultrasound Findings (2013) Ultrasonographic thyroid nodular findings in Japanese children. J Med Ultrason 40:219–224CrossRefGoogle Scholar
- Tronko M, Howe RW, Bogdanova TI, Bouville AC, Epstein OV, Brill AB, Likhtarev IA, Fink DJ, Markov VV, Greenebaum E, Olijnik VA, Masnyk IJ, Shpak VM, McConnell RJ, Tereschenko VP, Robbins J, Zvinchuk OV, Zablotska LB, Hatch M, Luckyanov NK, Thomas TL, Voilequé PG, Beebe GW (2006) A cohort study of thyroid cancer and other thyroid diseases after the Chornobyl accident: thyroid cancer in Ukraine detected during the first screening. J Natl Cancer Inst 98:897–903CrossRefGoogle Scholar
- UNSCEAR (2011) Sources and effects of ionizing radiation. UNSCEAR 2008 Report, Vol. II, Annex D. Health effects due to radiation from the Chernobyl accident. United Nations Scientific Committee on the Effects of Atomic Radiation, United Nations, New YorkGoogle Scholar
- U.S. Environmental Protection Agency (2011) EPA radiogenic cancer risk models and projections for the U.S. population. EPA 402-R-11-001Google Scholar
- Veiga LHS, Lubin JH, Anderson H, de Vathaire F, Tucker M, Bhatti P, Schneider A, Johansson R, Inskip P, Kleinerman R, Shore R, Pottern L, Holmberg E, Hawkins MM, Jacob Adams M, Sadetzki S, Lundell M, Sakata R, Damber L, Neta G, Ron E (2012) A pooled analysis of thyroid cancer incidence following radiotherapy for childhood cancer. Radiat Res 178:365–376CrossRefGoogle Scholar
- WHO (2012) Preliminary dose estimation from the nuclear accident after the 2011 Great East Japan earthquake and tsunami. World Health Organization, Geneva. http://apps.who.int/iris/bitstream/10665/44877/1/9789241503662_eng.pdf. Accessed 14 Mar 2013
- WHO (2013) Health risk assessment from the nuclear accident after the 2011 Great East Japan earthquake and tsunami based on a preliminary dose estimation. World Health Organization, Geneva. http://apps.who.int/iris/bitstream/10665/78218/1/9789241505130_eng.pdf. Accessed 14 Mar 2013
Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.